According to the Zhitong Finance App, Xinrui Pharmaceuticals (06108.HK) announced interim results for the six months ended June 30, 2026, with revenue of HK$113 million, up 153.7% year on year; net loss due to company owners was HK$3,565 million, a decrease of 52.2% year on year; basic loss per share was 1.78 HK cents.

According to the Zhitong Finance App, Xinrui Pharmaceuticals (06108.HK) announced interim results for the six months ended June 30, 2026, with revenue of HK$113 million, up 153.7% year on year; net loss due to company owners was HK$3,565 million, a decrease of 52.2% year on year; basic loss per share was 1.78 HK cents.